IDEXX Laboratories (NASDAQ:IDXX) Issues FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 14.290-14.800 for the period, compared to the consensus estimate of 14.450. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $670.46 on Monday. IDEXX Laboratories has a 52 week low of $356.14 and a 52 week high of $769.98. The company’s 50 day moving average price is $705.35 and its two-hundred day moving average price is $661.79. The stock has a market cap of $53.54 billion, a P/E ratio of 53.17, a P/E/G ratio of 3.58 and a beta of 1.67. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.IDEXX Laboratories’s revenue was up 13.3% on a year-over-year basis. During the same period last year, the business posted $2.80 earnings per share. On average, equities analysts predict that IDEXX Laboratories will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on IDXX shares. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. Barclays started coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They set an “overweight” rating and a $850.00 price target for the company. Morgan Stanley increased their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, UBS Group raised their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $763.50.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in IDEXX Laboratories during the third quarter valued at approximately $36,000. WealthCollab LLC bought a new position in IDEXX Laboratories during the second quarter valued at approximately $30,000. Johnson Financial Group Inc. raised its stake in shares of IDEXX Laboratories by 1,475.0% in the third quarter. Johnson Financial Group Inc. now owns 63 shares of the company’s stock valued at $40,000 after acquiring an additional 59 shares during the period. Finally, Pin Oak Investment Advisors Inc. purchased a new position in IDEXX Laboratories in the 3rd quarter worth about $60,000. Institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.